Jazz Pharmaceuticals 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bruce Cozadd

최고 경영자

US$15.3m

총 보상

CEO 급여 비율	7.8%
CEO 임기	22yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	5.4yrs
이사회 평균 재임 기간	11.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bruce Cozadd 의 보수는 Jazz Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$463m
Jun 30 2024	n/a	n/a	US$395m
Mar 31 2024	n/a	n/a	US$331m
Dec 31 2023	US$15m	US$1m	US$415m
Sep 30 2023	n/a	n/a	US$80m
Jun 30 2023	n/a	n/a	-US$87m
Mar 31 2023	n/a	n/a	-US$156m
Dec 31 2022	US$17m	US$1m	-US$224m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$450m
Dec 31 2021	US$16m	US$1m	-US$330m
Sep 30 2021	n/a	n/a	-US$161m
Jun 30 2021	n/a	n/a	US$40m
Mar 31 2021	n/a	n/a	US$518m
Dec 31 2020	US$13m	US$1m	US$239m
Sep 30 2020	n/a	n/a	US$179m
Jun 30 2020	n/a	n/a	US$133m
Mar 31 2020	n/a	n/a	US$280m
Dec 31 2019	US$15m	US$1m	US$523m
Sep 30 2019	n/a	n/a	US$609m
Jun 30 2019	n/a	n/a	US$656m
Mar 31 2019	n/a	n/a	US$486m
Dec 31 2018	US$11m	US$979k	US$447m

보상 대 시장: Bruce 의 총 보상 ($USD 15.34M )은 German 시장( $USD 3.30M ).

보상과 수익: Bruce 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Bruce Cozadd (60 yo)

22yrs

테뉴어

US$15,341,235

보상

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bruce Cozadd	Co-Founder	22yrs	US$15.34m	0.54% € 38.5m
Renee Gala	President & COO	1.3yrs	US$5.43m	0.028% € 2.0m
Patricia Carr	Senior VP & Chief Accounting Officer	5.4yrs	US$1.40m	데이터 없음
Neena Patil	Executive VP & Chief Legal Officer	5.5yrs	US$3.88m	0.012% € 862.9k
Robert Iannone	Executive VP	5.7yrs	US$4.98m	0.047% € 3.3m
Philip Johnson	Executive VP & CFO	less than a year	데이터 없음	0.020% € 1.4m
Andrea Flynn	VP & Head of Investor Relations	no data	데이터 없음	데이터 없음
Heidi Manna	Executive VP & Chief People Officer	6.2yrs	데이터 없음	데이터 없음
Jed Black	Senior Vice President of Sleep & CNS Medicine	no data	데이터 없음	데이터 없음
Samantha Pearce	Executive VP & Chief Commercial OfficerChief Commercial Officer	4.8yrs	데이터 없음	0.011% € 749.0k
John Miller	Senior Vice President of Corporate Strategy	5.3yrs	데이터 없음	데이터 없음
Mary Henderson	Senior Vice President of Technical Operations	1.4yrs	데이터 없음	0.0021% € 149.9k

5.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: J7Z 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bruce Cozadd	Co-Founder	22yrs	US$15.34m	0.54% € 38.5m
Kenneth O'Keefe	Independent Director	21yrs	US$513.77k	0.046% € 3.2m
Seamus Mulligan	Independent Director	13yrs	US$531.27k	1.93% € 136.8m
Norbert Riedel	Independent Director	11.7yrs	US$533.77k	0.020% € 1.4m
Patrick Gerald Enright	Independent Director	15.5yrs	US$526.27k	0.035% € 2.5m
Patrick Kennedy	Independent Director	less than a year	데이터 없음	데이터 없음
Rick Winningham	Lead Independent Director	14.7yrs	US$571.27k	0.015% € 1.0m
Jennifer Cook	Independent Non-Executive Director	4.1yrs	US$533.77k	0.0089% € 632.3k
Laura Hamill	Independent Director	less than a year	데이터 없음	0.0025% € 175.4k
Heather McSharry	Independent Director	11.7yrs	US$543.77k	0.025% € 1.8m
Mark Smith	Independent Non-Executive Director	4.1yrs	US$521.27k	0.0089% € 632.3k
Anne O'Riordan	Independent Director	5.9yrs	US$523.77k	0.018% € 1.3m

11.7yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: J7Z 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.7 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/04 08:37
장 마감 주가	2025/01/03 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Jazz Pharmaceuticals plc 51 애널리스트 중 19 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Joel Beatty	Baird
Ishan Majumdar	Baptista Research
Richard Silver	Barclays

Jazz Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025

Executive VP & Chief Legal Officer recently sold €426k worth of stock

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

Recent updates

Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025

Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits

Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?)

Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

New minor risk - Insider selling

Executive VP & Chief Legal Officer recently sold €426k worth of stock

Third quarter 2024 earnings released: EPS: US$3.50 (vs US$2.33 in 3Q 2023)

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024

Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Second quarter 2024 earnings released: EPS: US$2.68 (vs US$1.63 in 2Q 2023)

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index

Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

New minor risk - Insider selling

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab

Executive VP & Chief Legal Officer recently sold €509k worth of stock

First quarter 2024 earnings released: US$0.23 loss per share (vs US$1.09 profit in 1Q 2023)

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Senior VP & Chief Accounting Officer recently sold €401k worth of stock

Executive VP & CFO recently bought €1.3m worth of stock

New minor risk - Earnings quality

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: EPS: US$6.55 (vs US$3.58 loss in FY 2022)

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Insufficient new directors

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Third quarter 2023 earnings released: EPS: US$2.33 (vs US$0.31 loss in 3Q 2022)

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.63 (vs US$0.56 in 2Q 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Insider recently sold €734k worth of stock

First quarter 2023 earnings released: EPS: US$1.09 (vs US$0.027 in 1Q 2022)

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

Insider recently sold €276k worth of stock

Full year 2022 earnings released: US$3.58 loss per share (vs US$5.52 loss in FY 2021)

Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Insider recently sold €265k worth of stock

Independent Non-Executive Director recently sold €62k worth of stock

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting